483
Octapharma Plasma IncOctapharma Plasma Inc – FDA 483, Jan 10, 2024
Record Details
An FDA inspection of Octapharma Plasma Inc.'s plasmapheresis center in Cincinnati, OH, revealed a significant issue with adherence to written standard operating procedures. Specifically, employees failed to consistently follow procedures for visually inspecting refractometers for red blood cells during donor screening, potentially impacting the quality and safety of collected blood components. This indicates a breakdown in procedural compliance during critical donor evaluation steps.
- Person
View Company Profile
ID · 300e73f6-5f91-483a-b9c1-7078fb24c82f
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.